Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi-Aventis Sees India As Major Site For Diabetes Treatments

This article was originally published in PharmAsia News

Executive Summary

France's Sanofi-Aventis sees India as a possible base for the company's global effort to be a major player in diabetes treatments. In addition to beginning research into India-specific drug combinations and marketing of its Apidra (glulisine recombinant) insulin in India later this year, the firm also may make the country a global hub for its insulin manufacturing. The French drug maker already has a 7.9 percent market share for oral diabetes drugs and insulin through its Indian arm, Aventis Pharma. The subsidiary relies on a large Indian market for combination drugs, spurring the move to India-specific treatments. (Click here for more

You may also be interested in...



Indian CROs Move Up R&D Value Chain From Outsourcing Services To Partnering With MNCs

NEW DELHI - India, along with China, is increasingly becoming a popular destination for pharmaceutical research and development outsourced from the West, and more multinational companies are partnering with Indian CROs to improve productivity, cut costs and bring more drugs to market faster

‘Wrong Move’: Gottlieb Blasts Azar’s Perceived Regulatory Power Play Over FDA; HHS On Defense

The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”

US FDA Races To List Essential Medicines For Domestic Manufacture By White House Deadline

With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?

UsernamePublicRestriction

Register

MT101489

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel